Supply Channels are becoming more and more complex, and their models are evolving with an abundance of services to support both the providers and suppliers. The speed of approval and complexity of new oncology drugs continues. With this, comes increasing demands from stakeholders to ensure the right diagnosis, the right drug selection, the right safety and monitoring, and the right programs to support patients on sustained therapy. There are more stakeholders than ever before, all of whom want real-time information. What are the current opportunities within these channels and what will be some breakout offerings within the next few years?
